Brown, Lindsay A <br/><br/>
Co-amplification of CCND1 and EMSY is associated with an adverse outcome in ER-positive tamoxifen-treated breast cancers.  [electronic resource] 

 -  Breast cancer research and treatment  Jun 2010 
 - 347-54 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1573-7217 
<br/><br/><label>Standard No.: </label>10.1007/s10549-009-0479-x  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Biomarkers, Tumor--genetics<br/>Breast Neoplasms--drug therapy<br/>Cyclin D1--genetics<br/>Female<br/>Gene Amplification<br/>Genes, BRCA1<br/>Genes, BRCA2<br/>Humans<br/>In Situ Hybridization, Fluorescence<br/>Middle Aged<br/>Mutation<br/>Neoplasm Proteins--genetics<br/>Nuclear Proteins--genetics<br/>Prognosis<br/>Proportional Hazards Models<br/>Receptors, Estrogen--biosynthesis<br/>Repressor Proteins--genetics<br/>Selective Estrogen Receptor Modulators--therapeutic use<br/>Survival Analysis<br/>Tamoxifen--therapeutic use<br/>Tissue Array Analysis<br/>Treatment Outcome